MCID: NSS002
MIFTS: 53

Neisseria Meningitidis Infection

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neisseria Meningitidis Infection

MalaCards integrated aliases for Neisseria Meningitidis Infection:

Name: Neisseria Meningitidis Infection 53
Meningococcal Disease 53 3
Meningococcal Infections 73
Meningococcal Diseases 55

Classifications:



External Ids:

ICD10 33 A39.9
UMLS 73 C0025303

Summaries for Neisseria Meningitidis Infection

CDC : 3 Meningococcal disease can refer to any illness caused by the type of bacteria called Neisseria meningitidis, also known as meningococcus [muh-ning-goh-KOK-us]. These illnesses are often severe and can be deadly. They include infections of the lining of the brain and spinal cord (meningitis) and bloodstream infections (bacteremia or septicemia).

MalaCards based summary : Neisseria Meningitidis Infection, also known as meningococcal disease, is related to meningococcal meningitis and meningococcemia, and has symptoms including fever and pruritus. An important gene associated with Neisseria Meningitidis Infection is CFP (Complement Factor Properdin), and among its related pathways/superpathways are Innate Immune System and Influenza A. The drugs Histidine and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and b cells, and related phenotypes are hematopoietic system and immune system

Related Diseases for Neisseria Meningitidis Infection

Diseases related to Neisseria Meningitidis Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Related Disease Score Top Affiliating Genes
1 meningococcal meningitis 32.2 CFP MBL2
2 meningococcemia 32.1 CFP IL1RN MBL2
3 complement deficiency 30.1 C3 CD46 CFP MBL2
4 mannose-binding lectin deficiency 29.9 CFP MBL2
5 glomerulonephritis 29.6 C3 CD46 CFP
6 meningitis 29.6 CFP FCGR2A LACTB MBL2 OMP TLR2
7 pneumonia 28.9 DHPS LACTB MBL2 TLR2 TLR4
8 complement component 8 deficiency 11.6
9 meningococcal infection 11.5
10 properdin deficiency 11.3
11 c3 glomerulopathy 10.2 C3 CFP
12 scabies 10.2 CFP MBL2
13 complement component 3 deficiency 10.2 C3 CFP
14 deafness, autosomal recessive 24 10.2 EZR MSN
15 peripheral retinal degeneration 10.2 MBL2 ROM1
16 complement factor i deficiency 10.2 C3 CFP
17 coccidioidomycosis 10.2 MBL2 TLR4
18 pouchitis 10.1 IL1RN TLR4
19 3mc syndrome 10.1 CFP MBL2
20 influenza 10.1
21 haemophilus influenzae 10.1 OMP TLR2
22 cryopyrin-associated periodic syndrome 10.1 IL1R1 IL1RN
23 trench fever 10.1 TLR2 TLR4
24 schnitzler syndrome 10.1 IL1R1 IL1RN
25 fungal keratitis 10.1 TLR2 TLR4
26 acute cervicitis 10.1 TLR2 TLR4
27 neurofibromatosis, type ii 10.1 EZR MSN TLR2
28 streptococcal meningitis 10.1 CFP IL1R1 MBL2
29 bacteremia 2 10.1 LACTB MBL2
30 cardiac tamponade 10.1
31 waterhouse-friderichsen syndrome 10.1
32 anterior uveitis 10.1 TLR2 TLR4
33 suppurative otitis media 10.1 TLR2 TLR4
34 penicilliosis 10.0 TLR2 TLR4
35 tularemia 10.0 MBL2 TLR2
36 myositis fibrosa 10.0 TLR2 TLR4
37 aggressive periodontitis 10.0 FCGR2A IL1RN TLR4
38 vulvar vestibulitis syndrome 10.0 IL1R1 IL1RN MBL2
39 prosthetic joint infection 10.0 MBL2 TLR2 TLR4
40 invasive aspergillosis 10.0 MBL2 TLR2 TLR4
41 aspergillosis 10.0 MBL2 TLR2 TLR4
42 bacterial vaginosis 10.0 MBL2 TLR2 TLR4
43 membranoproliferative glomerulonephritis 10.0 C3 CD46 CFP
44 afibrinogenemia 10.0 C3 CD46 CFP
45 hemolytic uremic syndrome, atypical 1 10.0 C3 CD46 CFP
46 mycobacterium tuberculosis 1 10.0 MBL2 TLR2 TLR4
47 chorioamnionitis 10.0 IL1R1 IL1RN TLR4
48 properdin deficiency, x-linked 10.0
49 arthritis 10.0
50 purpura 10.0

Graphical network of the top 20 diseases related to Neisseria Meningitidis Infection:



Diseases related to Neisseria Meningitidis Infection

Symptoms & Phenotypes for Neisseria Meningitidis Infection

UMLS symptoms related to Neisseria Meningitidis Infection:


fever, pruritus

MGI Mouse Phenotypes related to Neisseria Meningitidis Infection:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 C3 DHPS EZR FCGR2A IL1R1 IL1RN
2 immune system MP:0005387 10.02 C3 CFP DHPS EZR FCGR2A IL1R1
3 cardiovascular system MP:0005385 10.01 C3 CD46 CFP IL1R1 IL1RN ROM1
4 mortality/aging MP:0010768 9.96 C3 CFP DHPS EZR FCGR2A IL1R1
5 normal MP:0002873 9.76 C3 CFP DHPS IL1R1 MSN OMP
6 renal/urinary system MP:0005367 9.43 C3 DHPS IL1R1 MBL2 TLR2 TLR4
7 skeleton MP:0005390 9.17 C3 CFP FCGR2A IL1R1 IL1RN TLR2

Drugs & Therapeutics for Neisseria Meningitidis Infection

Drugs for Neisseria Meningitidis Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
2
Lactitol Investigational Phase 4,Phase 3,Phase 2 585-86-4 3871
3 Complement Factor H Phase 4
4 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Antibodies Phase 4,Phase 3,Phase 2
7 Immunoglobulins Phase 4,Phase 3,Phase 2
8 Laxatives Phase 4,Phase 3,Phase 2
9 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Cathartics Phase 4,Phase 3,Phase 2
11 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
12
Hydroxocobalamin Approved Phase 3,Phase 2 13422-51-0 11953898 44475014
13
Acetaminophen Approved Phase 3 103-90-2 1983
14
Edetic Acid Approved, Vet_approved Phase 3 62-33-9, 60-00-4 6049
15
Iron Approved Phase 3 7439-89-6 23925
16
Pentetic acid Approved Phase 3 67-43-6
17
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2 68-19-9 44176380
18
Cobalamin Experimental Phase 3,Phase 2 13408-78-1 6438156
19 Complement System Proteins Phase 3
20 Vitamin B12 Phase 3,Phase 2
21 Vitamin B 12 Phase 3,Phase 2
22 Pharmaceutical Solutions Phase 3,Phase 2
23 Analgesics, Non-Narcotic Phase 3
24 Antipyretics Phase 3
25 Analgesics Phase 3
26 Peripheral Nervous System Agents Phase 3
27 Antidotes Phase 3
28 PENTA Phase 3
29 Fibrinolytic Agents Phase 3
30 Anticoagulants Phase 3
31 Chelating Agents Phase 3
32 Iron Chelating Agents Phase 3
33 Protective Agents Phase 3
34
Aluminum hydroxide Approved, Investigational Phase 2,Phase 1 21645-51-2
35 Antibodies, Monoclonal Phase 2
36 Antacids Phase 1
37 Adjuvants, Immunologic Phase 1
38 Anti-Ulcer Agents Phase 1
39
Salmon Calcitonin Approved, Investigational 47931-85-1 16129616
40
Calcitonin gene-related peptide Investigational 83652-28-2
41 Bone Density Conservation Agents
42 calcitonin

Interventional clinical trials:

(show top 50) (show all 122)
# Name Status NCT ID Phase Drugs
1 Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) Unknown status NCT02569632 Phase 4
2 Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine Unknown status NCT00262015 Phase 4
3 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
4 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Completed NCT01270503 Phase 4
5 Understanding the Immune Response to Two Different Meningitis Vaccines Completed NCT01593514 Phase 4
6 Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations Completed NCT02446691 Phase 4
7 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Completed NCT01823536 Phase 4
8 Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea Completed NCT01766206 Phase 4
9 Can we Reduce the Number of Vaccine Injections for Children? Completed NCT01129518 Phase 4
10 Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children Completed NCT01430611 Phase 4
11 Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage Completed NCT01119482 Phase 4
12 Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time Completed NCT00581035 Phase 4
13 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
14 Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years Completed NCT00290329 Phase 4
15 Immunogenicity of the Booster Dose of Two MenC Vaccines Completed NCT00392808 Phase 4
16 Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine Completed NCT00271479 Phase 4
17 South Australian Meningococcal B Vaccine Herd Immunity Study Recruiting NCT03089086 Phase 4
18 Adolescent MenACWY Booster Study Recruiting NCT03694405 Phase 4
19 A Sourcing Study to Collect Human Blood Samples From Healthy Adults Recruiting NCT03493919 Phase 4
20 Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B Active, not recruiting NCT03125616 Phase 4
21 A Study to Evaluate Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction Enrolling by invitation NCT02868970 Phase 4
22 Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. Completed NCT02141516 Phase 3
23 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. Completed NCT01911221 Phase 3
24 Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects Completed NCT01641042 Phase 3
25 Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. Completed NCT01682876 Phase 3
26 Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 Completed NCT01717638 Phase 3
27 One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age Completed NCT01139021 Phase 3
28 A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults Completed NCT01478347 Phase 3
29 Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers Completed NCT00847145 Phase 3
30 Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules Completed NCT00661713 Phase 2, Phase 3
31 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years Completed NCT01339923 Phase 3
32 Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 Completed NCT01148524 Phase 2, Phase 3
33 Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea Completed NCT01642589 Phase 3
34 Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. Completed NCT02173704 Phase 3
35 Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. Completed NCT01973218 Phase 3
36 Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia Completed NCT01725217 Phase 3
37 Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine Completed NCT01345721 Phase 3
38 A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months Completed NCT01000311 Phase 3
39 Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age Completed NCT00329849 Phase 3
40 Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years Completed NCT01423084 Phase 3
41 A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea Completed NCT01274897 Phase 3
42 Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life Completed NCT01214837 Phase 3
43 Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 Completed NCT00944034 Phase 2, Phase 3
44 Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years Completed NCT00329901 Phase 3
45 Understanding the Immune Response to Meningitis Vaccines Completed NCT00901940 Phase 3
46 A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years Completed NCT01830855 Phase 3
47 A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years. Completed NCT01352845 Phase 3
48 Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese Completed NCT03714737 Phase 3
49 Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine Completed NCT01453348 Phase 3
50 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3

Search NIH Clinical Center for Neisseria Meningitidis Infection

Genetic Tests for Neisseria Meningitidis Infection

Anatomical Context for Neisseria Meningitidis Infection

MalaCards organs/tissues related to Neisseria Meningitidis Infection:

41
Brain, Spinal Cord, B Cells, Testes, Bone, Endothelial, T Cells

Publications for Neisseria Meningitidis Infection

Articles related to Neisseria Meningitidis Infection:

(show top 50) (show all 1077)
# Title Authors Year
1
Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of Neisseria meningitidis infection. ( 29977064 )
2018
2
Invasive meningococcal disease due to a non-capsulated Neisseria meningitidis strain in a patient with IgG4-related disease. ( 29606119 )
2018
3
Invasive meningococcal disease without meningitis: a forgotten diagnosis. ( 29695936 )
2018
4
Differential influences of complement on neutrophil responses to N. meningitidis infection. ( 30476070 )
2018
5
Acquisition of virulence genes by a carrier strain gave rise to the ongoing epidemics of meningococcal disease in West Africa. ( 29735685 )
2018
6
The threat of meningococcal disease during the Hajj and Umrah mass gatherings: A comprehensive review. ( 29751133 )
2018
7
A probable prehistoric case of meningococcal disease from San Francisco Bay: Next generation sequencing of Neisseria meningitidis from dental calculus and osteological evidence. ( 29807684 )
2018
8
Mass chemoprophylaxis for control of outbreaks of meningococcal disease. ( 29858150 )
2018
9
Meningococcal Disease. ( 29867258 )
2018
10
Meningococcal Disease in Northern Ireland - Past, Present & Future: MeningoNI Forum. ( 29867259 )
2018
11
Meningococcal Disease Section 1: Microbiology And Historical Perspective: MeningoNI Forum (see page 87(2) 83 for full list of authors). ( 29867260 )
2018
12
Meningococcal Disease Section 2: Epidemiology and Vaccination of Meningococcal Disease in Northern Ireland: MeningoNI Forum (see page 87(2) 83 for full list of authors). ( 29867261 )
2018
13
Meningococcal Disease Section 3: Diagnosis and Management: MeningoNI Forum (see page 87(2) 83 for full list of authors). ( 29867262 )
2018
14
Meningococcal Disease Section 4: Post Disease Complications, Charity Support and Future Perspectives: MeningoNI Forum (see page 87(2) 83 for full list of authors). ( 29867263 )
2018
15
Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy. ( 29895504 )
2018
16
A protocol for a systematic review of the diagnostic accuracy of Loop-mediated-isothermal AMPlification (LAMP) in diagnosis of invasive meningococcal disease in children. ( 29903029 )
2018
17
Costs of Invasive Meningococcal Disease: A Global Systematic Review. ( 29948965 )
2018
18
Prevention of meningococcal disease at mass gatherings: Lessons from the Hajj and Umrah. ( 29954630 )
2018
19
Meningococcal disease burden and transmission in crowded settings and mass gatherings other than Hajj/Umrah: A systematic review. ( 29961604 )
2018
20
Epidemiology of meningococcal disease outbreaks in the United States, 2009-2013. ( 29982382 )
2018
21
Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination. ( 30017022 )
2018
22
In the Digital Era, Is Community Outrage a Feasible Proxy Indicator of Emotional Epidemiology? The Case of Meningococcal Disease in Sardinia, Italy. ( 30021934 )
2018
23
An outbreak of severe invasive meningococcal disease due to a capsular switched Neisseria meningitidis hypervirulent strain B:cc11. ( 30036673 )
2018
24
Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0. ( 30061891 )
2018
25
Invasive Meningococcal Disease Unraveling a Novel Mutation in the C5 Gene in a Portuguese Family. ( 30067596 )
2018
26
Emergence of Localized Serogroup W Meningococcal Disease in the United States - Georgia, 2006-2016. ( 30114000 )
2018
27
Invasive meningococcal disease in Shanghai, China from 1950 to 2016: implications for serogroup B vaccine implementation. ( 30120257 )
2018
28
Surveillance of invasive meningococcal disease based on whole genome sequencing (WGS), Czech Republic, 2015. ( 30126283 )
2018
29
Evaluation of Mass Vaccination Clinics in Response to a Serogroup B Meningococcal Disease Outbreak at a Large, Public University-Oregon, 2015. ( 30149923 )
2018
30
Interconnected clusters of invasive meningococcal disease due to Neisseria meningitidis serogroup C ST-11 (cc11), involving bisexuals and men who have sex with men, with discos and gay-venues hotspots of transmission, Tuscany, Italy, 2015 to 2016. ( 30153883 )
2018
31
Invasive meningococcal disease epidemiology and characterization of Neisseria meningitidis serogroups, sequence types, and clones; implication for use of meningococcal vaccines. ( 30156954 )
2018
32
Invasive Meningococcal Disease due to group C N. meningitidis ST11 (cc11): The Tuscany cluster 2015-2016. ( 30172636 )
2018
33
Author Correction: Invasive meningococcal disease in Shanghai, China from 1950 to 2016: implications for serogroup B vaccine implementation. ( 30177791 )
2018
34
Triplex Real-Time PCR without DNA Extraction for the Monitoring of Meningococcal Disease. ( 30200184 )
2018
35
Meningococcal Disease Surveillance in Men Who Have Sex with Men - United States, 2015-2016. ( 30260947 )
2018
36
Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers. ( 30267220 )
2018
37
Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. ( 30273506 )
2018
38
Societal costs due to meningococcal disease: a national registry-based study. ( 30323634 )
2018
39
Declining incidence of invasive meningococcal disease in South Africa: 2003-2016. ( 30351372 )
2018
40
No consistent increased mortality risk for females compared to males in invasive meningococcal disease in the European Surveillance System (TESSy). ( 30380019 )
2018
41
Invasive Meningococcal Disease in the Vaccine Era. ( 30474022 )
2018
42
Invasive meningococcal disease as a cause of sudden and unexpected death in a teenager: the public health importance of confirming the diagnosis. ( 30476492 )
2018
43
Tracking a serial killer: Integrating phylogenetic relationships, epidemiology, and geography for two invasive meningococcal disease outbreaks. ( 30485280 )
2018
44
The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. ( 30526162 )
2018
45
Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. ( 30526279 )
2018
46
Talk to Patients About: Meningococcal Disease. ( 30536244 )
2018
47
Emerging clinical experience with vaccines against group B meningococcal disease. ( 28778616 )
2018
48
Pros and cons of vaccination against serogroup B meningococcal disease. ( 28992986 )
2018
49
An epidemic of meningococcal disease in children in North Norway in the 1970s and 1980s was dominated by a hypervirulent group B strain. ( 29080366 )
2018
50
Potential role of IgM-enriched immunoglobulin as adjuvant treatment for invasive meningococcal disease. ( 29124316 )
2018

Variations for Neisseria Meningitidis Infection

Expression for Neisseria Meningitidis Infection

Search GEO for disease gene expression data for Neisseria Meningitidis Infection.

Pathways for Neisseria Meningitidis Infection

Pathways related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 C3 CD46 CFP FCGR2A IL1R1 IL1RN
2
Show member pathways
12.32 C3 CD46 CFP MSN TLR2 TLR4
3 12.08 EZR MSN TLR2 TLR4
4
Show member pathways
12.03 IL1R1 IL1RN TLR2
5
Show member pathways
12 EZR IL1R1 MSN TLR2 TLR4
6
Show member pathways
11.99 IL1R1 TLR2 TLR4
7
Show member pathways
11.98 C3 FCGR2A TLR2 TLR4
8 11.92 C3 FCGR2A TLR2 TLR4
9
Show member pathways
11.91 C3 CD46 MBL2
10 11.89 C3 CD46 MBL2
11
Show member pathways
11.85 IL1R1 TLR2 TLR4
12
Show member pathways
11.82 FCGR2A TLR2 TLR4
13
Show member pathways
11.81 IL1R1 TLR2 TLR4
14 11.78 FCGR2A IL1R1 TLR4
15
Show member pathways
11.75 C3 CD46 CFP MBL2
16 11.67 IL1R1 TLR2 TLR4
17
Show member pathways
11.58 C3 CD46 CFP MBL2
18 11.38 C3 FCGR2A MBL2
19 11.35 C3 TLR2 TLR4
20 11.2 C3 FCGR2A MBL2 TLR2 TLR4
21 11.19 C3 FCGR2A TLR2 TLR4
22 10.99 IL1R1 TLR2

GO Terms for Neisseria Meningitidis Infection

Cellular components related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vesicle GO:0031982 9.5 EZR IL1RN MSN
2 microvillus membrane GO:0031528 9.26 EZR MSN
3 uropod GO:0001931 9.16 EZR MSN
4 cell surface GO:0009986 9.1 CD46 IL1R1 MBL2 MSN TLR2 TLR4
5 invadopodium GO:0071437 8.96 EZR MSN

Biological processes related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.96 C3 CFP FCGR2A TLR2
2 immune system process GO:0002376 9.95 C3 CD46 MBL2 TLR2 TLR4
3 positive regulation of gene expression GO:0010628 9.83 CD46 EZR MSN TLR2 TLR4
4 complement activation, classical pathway GO:0006958 9.81 C3 CD46 MBL2
5 regulation of complement activation GO:0030449 9.78 C3 CD46 CFP
6 inflammatory response GO:0006954 9.77 C3 IL1R1 IL1RN TLR2 TLR4
7 complement activation GO:0006956 9.73 C3 CFP MBL2
8 leukocyte cell-cell adhesion GO:0007159 9.65 EZR MSN
9 positive regulation of interleukin-8 production GO:0032757 9.65 TLR2 TLR4
10 positive regulation of interleukin-6 production GO:0032755 9.65 IL1RN TLR2 TLR4
11 positive regulation of interferon-beta production GO:0032728 9.64 TLR2 TLR4
12 positive regulation of interleukin-12 production GO:0032735 9.63 TLR2 TLR4
13 regulation of cell size GO:0008361 9.63 EZR MSN
14 positive regulation of chemokine production GO:0032722 9.62 TLR2 TLR4
15 establishment of endothelial barrier GO:0061028 9.62 EZR MSN
16 establishment of epithelial cell apical/basal polarity GO:0045198 9.61 EZR MSN
17 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.6 TLR2 TLR4
18 complement activation, alternative pathway GO:0006957 9.59 C3 CFP
19 positive regulation of cellular protein catabolic process GO:1903364 9.58 EZR MSN
20 regulation of cytokine secretion GO:0050707 9.58 TLR2 TLR4
21 I-kappaB phosphorylation GO:0007252 9.57 TLR2 TLR4
22 cellular response to lipoteichoic acid GO:0071223 9.54 TLR2 TLR4
23 gland morphogenesis GO:0022612 9.52 EZR MSN
24 positive regulation of early endosome to late endosome transport GO:2000643 9.51 EZR MSN
25 positive regulation of protein localization to early endosome GO:1902966 9.49 EZR MSN
26 membrane to membrane docking GO:0022614 9.46 EZR MSN
27 innate immune response GO:0045087 9.43 C3 CD46 CFP MBL2 TLR2 TLR4
28 regulation of organelle assembly GO:1902115 9.4 EZR MSN
29 positive regulation of interleukin-10 production GO:0032733 9.33 CD46 TLR2 TLR4
30 interleukin-10 production GO:0032613 9.32 CD46 TLR2
31 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.26 TLR2 TLR4
32 immune response GO:0006955 9.1 C3 CFP IL1R1 IL1RN TLR2 TLR4

Molecular functions related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.26 C3 MBL2 MSN TLR4
2 lipopolysaccharide receptor activity GO:0001875 8.62 TLR2 TLR4

Sources for Neisseria Meningitidis Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....